Gerresheimer Stock - Goldman Sachs lifts voting stake to 20%
Published on 06/21/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 13:23 CET. Details in the imprint.
Gerresheimer (DE000A0LD6E6) moves back into the headlines after a significant shareholder reshuffle. A recent BaFin notification shows that Goldman Sachs has lifted its voting stake to just above 20%, signaling confidence in the specialist packaging group in a demanding market environment.
All news and key data on Gerresheimer stock
From major shareholder moves like the new Goldman Sachs stake to earnings dates and index status, our topic page bundles background and current figures on Gerresheimer stock.
Goldman Sachs lifts stake
According to a BaFin voting rights notification referenced by German financial media, Goldman Sachs has increased its Gerresheimer stake to 20.05% of the voting rights, effective 06/08/2026. A detailed Börse Global report highlights the threshold crossing, which was published in mid-June as a mandatory filing.
The step moves the US bank into the role of a core shareholder alongside long-term investors in the German mid-cap. For a company of Gerresheimer’s size, a 20% voting bloc is substantial and can matter in strategic discussions, from capital allocation to board composition.
Background on ownership and positioning
Gerresheimer has long been positioned as a specialist partner to the pharma and biotech industries, supplying primary packaging and drug-delivery solutions worldwide. Company information describes a focus on high-value pharmaceutical packaging, medical devices and related services, with a footprint across Europe, the Americas and emerging markets.
In this context, the enlarged Goldman Sachs stake can be read as a vote of confidence in the structural demand the group serves, from injectable drugs to complex biologics. All told, a major financial shareholder taking on 20% is a clear signal in an otherwise volatile mid-cap environment.
How the company makes money
Gerresheimer generates revenue primarily with specialty glass and plastic packaging for injectable drugs, insulin, vaccines and other pharmaceuticals, as well as prefillable syringes, vials and drug-delivery systems for biotech and healthcare customers worldwide.
Where the stock trades today
The shares of Gerresheimer (DE000A0LD6E6) trade on Xetra at EUR 103.40 as of 06/21/2026, 13:23 CET.
Key facts on Gerresheimer stock
- Company: Gerresheimer AG
- ISIN: DE000A0LD6E6
- WKN: A0LD6E
- Ticker: GXI
- Venue: Xetra
- Price (as of 06/21/2026, 13:23 CET): 103.40 EUR
- Market cap: 3,230,000,000 EUR (as of 06/21/2026)
- Sector / Industry: Health Care - Medical Supplies & Packaging
- Index membership: MDAX, Stoxx Europe 600
- Next earnings date: 07/11/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
